222 related articles for article (PubMed ID: 37835463)
21. Prediction Models for Complete Resection in Secondary Cytoreductive Surgery of Patients With Recurrent Ovarian Cancer.
Jiang C; Li Z
Front Oncol; 2021; 11():674637. PubMed ID: 34631517
[TBL] [Abstract][Full Text] [Related]
22. [How to increase the optimal rate of secondary cytoreductive surgery in recurrent epithelial ovarian cancer].
Li YF; Li MD; Liu FY; Liu JH; Li JD
Ai Zheng; 2003 Nov; 22(11):1193-6. PubMed ID: 14613651
[TBL] [Abstract][Full Text] [Related]
23. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
Felsinger M; Minar L; Weinberger V; Rovny I; Zlamal F; Bienertova-Vasku J
Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():154-160. PubMed ID: 29957400
[TBL] [Abstract][Full Text] [Related]
24. Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers.
Minaguchi T; Satoh T; Matsumoto K; Sakurai M; Ochi H; Onuki M; Oki A; Yoshikawa H
Int J Clin Oncol; 2016 Jun; 21(3):573-9. PubMed ID: 26475355
[TBL] [Abstract][Full Text] [Related]
25. Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer?
Kumar S; Srinivasan A; Phillips A; Madhupriya R; Pascoe J; Nevin J; Elattar A; Balega J; Cummins C; Sundar S; Kehoe ST; Singh K
J Obstet Gynaecol; 2020 Aug; 40(6):849-855. PubMed ID: 31933417
[TBL] [Abstract][Full Text] [Related]
26. Robotic surgery in ovarian cancer.
Gallotta V; Certelli C; Oliva R; Rosati A; Federico A; Loverro M; Lodoli C; Foschi N; Lathouras K; Fagotti A; Scambia G
Best Pract Res Clin Obstet Gynaecol; 2023 Aug; 90():102391. PubMed ID: 37573801
[TBL] [Abstract][Full Text] [Related]
27. Robotic surgery for ovarian cancers: individualization of the surgical approach to select ovarian cancer patients.
Rabinovich A
Int J Med Robot; 2016 Sep; 12(3):547-53. PubMed ID: 26173832
[TBL] [Abstract][Full Text] [Related]
28. The Role of Minimally Invasive Surgery in the Care of Women with Ovarian Cancer: A Systematic Review and Meta-analysis.
Knisely A; Gamble CR; St Clair CM; Hou JY; Khoury-Collado F; Gockley AA; Wright JD; Melamed A
J Minim Invasive Gynecol; 2021 Mar; 28(3):537-543. PubMed ID: 33202311
[TBL] [Abstract][Full Text] [Related]
29. Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer.
Jeong SY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS; Lee YY
J Ovarian Res; 2019 Dec; 13(1):1. PubMed ID: 31892329
[TBL] [Abstract][Full Text] [Related]
30. Secondary cytoreductive surgery in recurrent clear cell carcinoma of the endometrium: A case report.
Cheng C; Jenkins N; Aikman N; ElSahwi K
Int J Surg Case Rep; 2023 Jul; 108():108412. PubMed ID: 37418794
[TBL] [Abstract][Full Text] [Related]
31. The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery.
Bizzarri N; Marchetti C; Conte C; Loverro M; Giudice MT; Quagliozzi L; Distefano M; Chiantera V; Scambia G; Fagotti A
Gynecol Oncol; 2022 Jun; 165(3):453-458. PubMed ID: 35397918
[TBL] [Abstract][Full Text] [Related]
32. Survival Impact of Secondary Cytoreductive Surgery for Recurrent Ovarian Cancer in an Asian Population.
Bhat RA; Chia YN; Lim YK; Yam KL; Lim C; Teo M
Oman Med J; 2015 Sep; 30(5):344-52. PubMed ID: 26421115
[TBL] [Abstract][Full Text] [Related]
33. HE4 and eIF3a Expression Correlates with Surgical Outcome and Overall Survival in Ovarian Cancer Patients with Secondary Cytoreduction.
Luo CH; Zhao M; Chen XY; Shahabi S; Qiang W; Zeng L; Wang J; Zhou HH
J Cancer; 2018; 9(14):2472-2479. PubMed ID: 30026845
[TBL] [Abstract][Full Text] [Related]
34. Feasibility and perioperative outcomes of robotic-assisted surgery in the management of recurrent ovarian cancer: a multi-institutional study.
Escobar PF; Levinson KL; Magrina J; Martino MA; Barakat RR; Fader AN; Leitao MM
Gynecol Oncol; 2014 Aug; 134(2):253-6. PubMed ID: 24844594
[TBL] [Abstract][Full Text] [Related]
35. The role of surgery in platinum-resistant ovarian cancer: A call to the scientific community.
Petrillo M; Sozzi G; Dessole M; Capobianco G; Dessole S; Madonia M; Cherchi PL; Paoletti AM; Scambia G; Chiantera V
Semin Cancer Biol; 2021 Dec; 77():194-202. PubMed ID: 33607247
[TBL] [Abstract][Full Text] [Related]
36. The current role of secondary cytoreductive surgery for recurrent ovarian cancer.
de Bree E; Michelakis D; Anagnostopoulou E
Front Oncol; 2022; 12():1029976. PubMed ID: 36338689
[TBL] [Abstract][Full Text] [Related]
37. Robotic resection of isolated ovarian cancer recurrence in the lesser sac.
St Laurent JD; Silberman JN; Worley MJ
Gynecol Oncol Rep; 2022 Jun; 41():100991. PubMed ID: 35638095
[TBL] [Abstract][Full Text] [Related]
38. Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis.
Goldberg RM; Kim SR; Fazelzad R; Li X; Brown TJ; May T
Gynecol Oncol; 2022 Jan; 164(1):212-220. PubMed ID: 34756470
[TBL] [Abstract][Full Text] [Related]
39. Laparoscopic splenectomy for secondary cytoreduction of ovarian cancer in a woman with localized splenic recurrence.
Acosta-Torres S; Fader AN
Gynecol Oncol; 2020 Mar; 156(3):744-745. PubMed ID: 31955860
[TBL] [Abstract][Full Text] [Related]
40. Pancreatic Resection as Part of Cytoreductive Surgery in Advanced-stage and Recurrent Epithelial Ovarian Cancer--A Single-center Experience.
Bacalbasa N; Balescu I; Dima S; Brasoveanu V; Popescu I
Anticancer Res; 2015 Jul; 35(7):4125-9. PubMed ID: 26124365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
